FindTrial
Sign In

Henagliflozin

DRUG7 trials

Sponsors

First Affiliated Hospital of Guangxi Medical University, Qianfoshan Hospital, RenJi Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Qian geng

Conditions

Diabetic NephropathiesHeart FailureMagnetic Resonance ImagingMild Cognitive ImpairmentMyocardial FibrosisMyocardial InfarctionNon-Alcoholic Fatty Liver DiseaseObese

Phase 4

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
CompletedNCT05677334
First Affiliated Hospital of Guangxi Medical UniversityType2diabetes
Start: 2023-03-01End: 2024-10-30Updated: 2025-03-12
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
CompletedNCT06187727
Qian gengHeart Failure, Myocardial Infarction
Start: 2023-07-01End: 2025-10-01Updated: 2025-12-02
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
Not yet recruitingNCT06216340
The First People's Hospital of ChangzhouObese, Pre-diabetes, Weight Loss
Start: 2024-02-15End: 2026-10-01Target: 300Updated: 2024-01-22
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Not yet recruitingNCT06218342
Sir Run Run Shaw HospitalNon-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Start: 2024-02-15End: 2025-12-31Target: 156Updated: 2024-01-23

Unknown Phase

Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
NCT06031389
Qianfoshan HospitalDiabetic Nephropathies
Start: 2024-01-01End: 2025-12-31Target: 120Updated: 2023-09-11
The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
NCT06059287
RenJi HospitalMagnetic Resonance Imaging, Myocardial Fibrosis, Obesity +2
Start: 2023-10-01End: 2025-12-31Target: 64Updated: 2023-09-28
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
CompletedNCT06085703
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMild Cognitive Impairment, Type 2 Diabetes Mellitus
Start: 2024-04-01End: 2025-06-30Updated: 2025-07-10

Related Papers

A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia.
2026-03-19
Efficacy and safety of henagliflozin combined with continuous subcutaneous insulin infusion in the treatment of Chinese inpatients with type 2 diabetes mellitus based on a continuous glucose monitoring system: protocol of a multicentre, open-label, inpatient, randomised, controlled trial
BMJ Open2024-10-011 citations